25 XP   0   0   10

Zentalis Pharmaceuticals Llc
Buy, Hold or Sell?

Let's analyse Zentalis together

PenkeI guess you are interested in Zentalis Pharmaceuticals Llc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Zentalis Pharmaceuticals Llc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Zentalis Pharmaceuticals Llc

I send you an email if I find something interesting about Zentalis Pharmaceuticals Llc.

Quick analysis of Zentalis (30 sec.)










What can you expect buying and holding a share of Zentalis? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.16
Expected worth in 1 year
$6.21
How sure are you?
41.2%

+ What do you gain per year?

Total Gains per Share
$0.05
Return On Investment
0.4%

For what price can you sell your share?

Current Price per Share
$12.71
Expected price per share
$9.56 - $16.27
How sure are you?
50%

1. Valuation of Zentalis (5 min.)




Live pricePrice per Share (EOD)

$12.71

Intrinsic Value Per Share

$-27.28 - $-31.76

Total Value Per Share

$-21.11 - $-25.60

2. Growth of Zentalis (5 min.)




Is Zentalis growing?

Current yearPrevious yearGrowGrow %
How rich?$437.3m$412.8m$44.2m9.7%

How much money is Zentalis making?

Current yearPrevious yearGrowGrow %
Making money-$72.4m-$55.2m-$17.2m-23.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Zentalis (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#129 / 1019

Most Revenue
#816 / 1019

Most Profit
#938 / 1019

Most Efficient
#169 / 1019

What can you expect buying and holding a share of Zentalis? (5 min.)

Welcome investor! Zentalis's management wants to use your money to grow the business. In return you get a share of Zentalis.

What can you expect buying and holding a share of Zentalis?

First you should know what it really means to hold a share of Zentalis. And how you can make/lose money.

Speculation

The Price per Share of Zentalis is $12.71. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zentalis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zentalis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.16. Based on the TTM, the Book Value Change Per Share is $0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zentalis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.86-6.8%-1.03-8.1%-0.83-6.6%-0.68-5.3%-0.68-5.3%
Usd Book Value Change Per Share-0.63-4.9%0.010.1%0.251.9%0.362.9%0.362.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.63-4.9%0.010.1%0.251.9%0.362.9%0.362.9%
Usd Price Per Share15.15-20.16-29.01-33.92-33.92-
Price to Earnings Ratio-4.41--5.02--8.68--27.69--27.69-
Price-to-Total Gains Ratio-24.16--17.31-45.28--20.16--20.16-
Price to Book Ratio2.46-3.10-5.37-7.04-7.04-
Price-to-Total Gains Ratio-24.16--17.31-45.28--20.16--20.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share12.71
Number of shares78
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.36
Usd Total Gains Per Share0.010.36
Gains per Quarter (78 shares)0.9328.28
Gains per Year (78 shares)3.70113.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104-60113103
207-20226216
301120339329
401560453442
5019100566555
6022140679668
7026180792781
8030220905894
903326010181007
1003730011311120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.010.00.041.2%7.010.00.041.2%7.010.00.041.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%7.010.00.041.2%7.010.00.041.2%7.010.00.041.2%

Fundamentals of Zentalis

About Zentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2024-04-13 03:49:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Zentalis Pharmaceuticals Llc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Zentalis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Zentalis to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zentalis Pharmaceuticals Llc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y--436.8%+436.8%
10Y--599.3%+599.3%
1.1.2. Return on Assets

Shows how efficient Zentalis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zentalis to the Biotechnology industry mean.
  • -10.8% Return on Assets means that Zentalis generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zentalis Pharmaceuticals Llc:

  • The MRQ is -10.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.8%TTM-12.7%+1.9%
TTM-12.7%YOY-11.0%-1.7%
TTM-12.7%5Y-12.0%-0.7%
5Y-12.0%10Y-12.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.8%-13.6%+2.8%
TTM-12.7%-12.9%+0.2%
YOY-11.0%-11.9%+0.9%
5Y-12.0%-14.2%+2.2%
10Y-12.0%-16.2%+4.2%
1.1.3. Return on Equity

Shows how efficient Zentalis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zentalis to the Biotechnology industry mean.
  • -13.9% Return on Equity means Zentalis generated $-0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zentalis Pharmaceuticals Llc:

  • The MRQ is -13.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.9%TTM-15.7%+1.8%
TTM-15.7%YOY-13.7%-2.0%
TTM-15.7%5Y-13.5%-2.2%
5Y-13.5%10Y-13.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.9%-17.0%+3.1%
TTM-15.7%-16.1%+0.4%
YOY-13.7%-15.4%+1.7%
5Y-13.5%-20.0%+6.5%
10Y-13.5%-21.1%+7.6%

1.2. Operating Efficiency of Zentalis Pharmaceuticals Llc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Zentalis is operating .

  • Measures how much profit Zentalis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zentalis to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zentalis Pharmaceuticals Llc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y--475.2%+475.2%
10Y--624.7%+624.7%
1.2.2. Operating Ratio

Measures how efficient Zentalis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Zentalis Pharmaceuticals Llc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y-5.675-5.675
10Y-7.857-7.857

1.3. Liquidity of Zentalis Pharmaceuticals Llc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Zentalis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.16 means the company has $7.16 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Zentalis Pharmaceuticals Llc:

  • The MRQ is 7.161. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.575. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.161TTM8.575-1.415
TTM8.575YOY8.137+0.438
TTM8.5755Y9.059-0.483
5Y9.05910Y9.0590.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1613.930+3.231
TTM8.5754.251+4.324
YOY8.1375.436+2.701
5Y9.0596.045+3.014
10Y9.0596.363+2.696
1.3.2. Quick Ratio

Measures if Zentalis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zentalis to the Biotechnology industry mean.
  • A Quick Ratio of 13.52 means the company can pay off $13.52 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zentalis Pharmaceuticals Llc:

  • The MRQ is 13.519. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.691. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ13.519TTM14.691-1.172
TTM14.691YOY15.023-0.332
TTM14.6915Y15.487-0.796
5Y15.48710Y15.4870.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.5193.629+9.890
TTM14.6914.065+10.626
YOY15.0235.397+9.626
5Y15.4875.993+9.494
10Y15.4876.277+9.210

1.4. Solvency of Zentalis Pharmaceuticals Llc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Zentalis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zentalis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.22 means that Zentalis assets are financed with 22.2% credit (debt) and the remaining percentage (100% - 22.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zentalis Pharmaceuticals Llc:

  • The MRQ is 0.222. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.192. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.222TTM0.192+0.030
TTM0.192YOY0.194-0.001
TTM0.1925Y0.265-0.073
5Y0.26510Y0.2650.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2220.332-0.110
TTM0.1920.334-0.142
YOY0.1940.268-0.074
5Y0.2650.366-0.101
10Y0.2650.390-0.125
1.4.2. Debt to Equity Ratio

Measures if Zentalis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zentalis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 28.5% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zentalis Pharmaceuticals Llc:

  • The MRQ is 0.285. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.239. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.285TTM0.239+0.046
TTM0.239YOY0.241-0.002
TTM0.2395Y0.181+0.058
5Y0.18110Y0.1810.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2850.381-0.096
TTM0.2390.390-0.151
YOY0.2410.334-0.093
5Y0.1810.434-0.253
10Y0.1810.466-0.285

2. Market Valuation of Zentalis Pharmaceuticals Llc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Zentalis generates.

  • Above 15 is considered overpriced but always compare Zentalis to the Biotechnology industry mean.
  • A PE ratio of -4.41 means the investor is paying $-4.41 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zentalis Pharmaceuticals Llc:

  • The EOD is -3.701. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.412. Based on the earnings, the company is expensive. -2
  • The TTM is -5.024. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.701MRQ-4.412+0.711
MRQ-4.412TTM-5.024+0.612
TTM-5.024YOY-8.678+3.654
TTM-5.0245Y-27.692+22.668
5Y-27.69210Y-27.6920.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.701-2.315-1.386
MRQ-4.412-2.560-1.852
TTM-5.024-2.664-2.360
YOY-8.678-4.122-4.556
5Y-27.692-6.258-21.434
10Y-27.692-6.108-21.584
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zentalis Pharmaceuticals Llc:

  • The EOD is -5.530. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.592. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.063. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.530MRQ-6.592+1.062
MRQ-6.592TTM-7.063+0.471
TTM-7.063YOY-12.057+4.993
TTM-7.0635Y-16.899+9.836
5Y-16.89910Y-16.8990.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.530-3.067-2.463
MRQ-6.592-3.251-3.341
TTM-7.063-3.545-3.518
YOY-12.057-5.595-6.462
5Y-16.899-8.315-8.584
10Y-16.899-8.708-8.191
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Zentalis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.46 means the investor is paying $2.46 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Zentalis Pharmaceuticals Llc:

  • The EOD is 2.062. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.458. Based on the equity, the company is underpriced. +1
  • The TTM is 3.100. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.062MRQ2.458-0.396
MRQ2.458TTM3.100-0.643
TTM3.100YOY5.367-2.266
TTM3.1005Y7.042-3.942
5Y7.04210Y7.0420.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0621.905+0.157
MRQ2.4582.111+0.347
TTM3.1002.095+1.005
YOY5.3672.836+2.531
5Y7.0423.443+3.599
10Y7.0423.794+3.248
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Zentalis Pharmaceuticals Llc.

3.1. Institutions holding Zentalis Pharmaceuticals Llc

Institutions are holding 114.891% of the shares of Zentalis Pharmaceuticals Llc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Matrix Capital Management Company, LLC19.6732.17681395997300
2023-12-31Eventide Asset Management, LLC16.29082.858611559975374593647.9385
2023-12-31FMR Inc14.56730.012103369718430758.8802
2023-12-31Vanguard Group Inc7.54010.001853504581137952.173
2023-12-31BlackRock Inc6.60230.001846849752891186.5771
2023-12-31State Street Corporation6.22470.00334417056171369663.3913
2023-12-31T. Rowe Price Associates, Inc.4.09250.005929040651884666.9401
2023-12-31Capital Research & Mgmt Co - Division 33.97360.00962819664-308094-9.8503
2023-12-31T. Rowe Price Investment Management,Inc.3.30010.0231234178336929918.7225
2023-12-31Federated Hermes Inc3.04480.0813216056521287210.9294
2023-09-30Citadel Advisors Llc3.03740.00932155351260551.2236
2023-12-31Decheng Capital LLC2.95888.8871209958320995830
2023-12-31Woodline Partners LP1.97790.2312140355340355340.3553
2023-12-31Geode Capital Management, LLC1.76680.0021253737669005.6368
2023-12-31PRIMECAP Management Company1.44210.01231023350-10400-1.006
2023-12-31Tybourne Capital Management (HK) Ltd1.3552.170496148600
2023-12-31Dimensional Fund Advisors, Inc.1.02030.003272403323971449.4951
2023-12-31Bank of America Corp1.01270.0011718643485680208.4795
2023-12-31Morgan Stanley - Brokerage Accounts0.85890.00086094836386311.7047
2023-12-31Goldman Sachs Group Inc0.82550.0008585762362501162.3665
Total 101.564616.492472070466+10905612+15.1%

3.2. Funds holding Zentalis Pharmaceuticals Llc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Eventide Healthcare & Life Sciences I9.27465.98176581258164625833.3588
2023-12-31Eventide Gilead N7.01261.97024976164209913072.9616
2023-12-31American Funds SMALLCAP World A3.97360.05942819664-991094-26.0078
2024-03-28SPDR® S&P Biotech ETF3.49890.51822482824313201.2776
2024-02-29Vanguard Total Stock Mkt Idx Inv2.33130.0016165431900
2024-03-28iShares Russell 2000 ETF2.01510.034414298896900.0483
2024-02-29Vanguard Small Cap Index1.92770.01451367892125690.9274
2023-12-31Federated Hermes Kaufmann Small Cap Grow1.67120.4272118590019943920.2176
2023-12-31Federated Hermes Kaufmann Small Cap A1.67120.4272118590019943920.2176
2024-02-29Fidelity Growth Compy Commingled Pl O1.62950.022115628300
2023-12-31T. Rowe Price New Horizons1.55330.06751102232261492.43
2023-12-31US Small-Cap Growth II Equity Comp1.55330.06731102232261492.43
2023-12-31T. Rowe Price Health Sciences1.34040.098951165835079.6244
2023-12-31Federated Hermes Kaufmann R1.33880.2951950000124681.3299
2023-12-31Federated Hermes Kaufmann Growth1.33880.2951950000124681.3299
2024-02-29Fidelity Growth Company Fund1.28210.022790979100
2024-02-29Fidelity Select Health Care1.26830.169590000000
2024-02-29Fidelity Advisor Growth Opps M1.24990.065288690000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.19230.01248460425000.0591
2024-02-29Vanguard Small Cap Growth Index Inv1.08210.0328767850127631.6903
Total 48.20510.58234206305+3371755+9.9%

3.3. Insider Transactions

Insiders are holding 4.222% of the shares of Zentalis Pharmaceuticals Llc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-12Cam GallagherSELL117311.44
2024-02-12Melissa B EpperlySELL257311.44
2023-11-13Kimberly BlackwellBUY500010.29
2023-11-10David Michael JohnsonBUY170009.88
2023-10-04Carrie BrownsteinSELL1062819.5
2023-10-04Melissa B EpperlySELL548219.5
2023-09-11Jan SkvarkaSELL500025.05
2023-06-20Matrix Capital Management CompBUY476000022.66
2023-05-31Cam GallagherSELL2776826.27
2023-05-26Kevin D BunkerSELL8000030.02

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Zentalis Pharmaceuticals Llc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.6270.012-5387%0.245-356%0.363-273%0.363-273%
Book Value Per Share--6.1646.441-4%5.818+6%4.733+30%4.733+30%
Current Ratio--7.1618.575-16%8.137-12%9.059-21%9.059-21%
Debt To Asset Ratio--0.2220.192+15%0.194+15%0.265-16%0.265-16%
Debt To Equity Ratio--0.2850.239+19%0.241+18%0.181+57%0.181+57%
Dividend Per Share----0%-0%-0%-0%
Eps---0.858-1.029+20%-0.834-3%-0.680-21%-0.680-21%
Free Cash Flow Per Share---0.575-0.734+28%-0.586+2%-0.527-8%-0.527-8%
Free Cash Flow To Equity Per Share---0.5750.102-664%0.334-272%0.332-273%0.332-273%
Gross Profit Margin--1.0061.001+0%1.000+1%1.000+1%1.000+1%
Intrinsic Value_10Y_max---31.759--------
Intrinsic Value_10Y_min---27.275--------
Intrinsic Value_1Y_max---2.613--------
Intrinsic Value_1Y_min---2.567--------
Intrinsic Value_3Y_max---8.286--------
Intrinsic Value_3Y_min---7.901--------
Intrinsic Value_5Y_max---14.481--------
Intrinsic Value_5Y_min---13.404--------
Market Cap901904142.000-19%1075047030.0001430202831.000-25%2058555402.000-48%2406803018.824-55%2406803018.824-55%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio2.062-19%2.4583.100-21%5.367-54%7.042-65%7.042-65%
Pe Ratio-3.701+16%-4.412-5.024+14%-8.678+97%-27.692+528%-27.692+528%
Price Per Share12.710-19%15.15020.155-25%29.010-48%33.918-55%33.918-55%
Price To Free Cash Flow Ratio-5.530+16%-6.592-7.063+7%-12.057+83%-16.899+156%-16.899+156%
Price To Total Gains Ratio-20.265+16%-24.155-17.311-28%45.279-153%-20.157-17%-20.157-17%
Quick Ratio--13.51914.691-8%15.023-10%15.487-13%15.487-13%
Return On Assets---0.108-0.127+17%-0.110+2%-0.120+11%-0.120+11%
Return On Equity---0.139-0.157+13%-0.137-2%-0.135-3%-0.135-3%
Total Gains Per Share---0.6270.012-5387%0.245-356%0.363-273%0.363-273%
Usd Book Value--437391000.000457058750.000-4%412812750.000+6%335867764.706+30%335867764.706+30%
Usd Book Value Change Per Share---0.6270.012-5387%0.245-356%0.363-273%0.363-273%
Usd Book Value Per Share--6.1646.441-4%5.818+6%4.733+30%4.733+30%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.858-1.029+20%-0.834-3%-0.680-21%-0.680-21%
Usd Free Cash Flow---40772000.000-52101250.000+28%-41574750.000+2%-37394941.176-8%-37394941.176-8%
Usd Free Cash Flow Per Share---0.575-0.734+28%-0.586+2%-0.527-8%-0.527-8%
Usd Free Cash Flow To Equity Per Share---0.5750.102-664%0.334-272%0.332-273%0.332-273%
Usd Market Cap901904142.000-19%1075047030.0001430202831.000-25%2058555402.000-48%2406803018.824-55%2406803018.824-55%
Usd Price Per Share12.710-19%15.15020.155-25%29.010-48%33.918-55%33.918-55%
Usd Profit---60917000.000-72481000.000+19%-55207750.000-9%-47166294.118-23%-47166294.118-23%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.6270.012-5387%0.245-356%0.363-273%0.363-273%
 EOD+3 -5MRQTTM+11 -19YOY+10 -205Y+8 -2210Y+8 -22

4.2. Fundamental Score

Let's check the fundamental score of Zentalis Pharmaceuticals Llc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.701
Price to Book Ratio (EOD)Between0-12.062
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than113.519
Current Ratio (MRQ)Greater than17.161
Debt to Asset Ratio (MRQ)Less than10.222
Debt to Equity Ratio (MRQ)Less than10.285
Return on Equity (MRQ)Greater than0.15-0.139
Return on Assets (MRQ)Greater than0.05-0.108
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Zentalis Pharmaceuticals Llc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.810
Ma 20Greater thanMa 5014.352
Ma 50Greater thanMa 10013.924
Ma 100Greater thanMa 20013.643
OpenGreater thanClose13.030
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Current Deferred Revenue -2,162-85-2,247-88-2,335-90-2,4252,706281
Accumulated Other Comprehensive Income  -1,353797-556218-338-21-3592,5532,194



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets562,027
Total Liabilities124,636
Total Stockholder Equity437,284
 As reported
Total Liabilities 124,636
Total Stockholder Equity+ 437,284
Total Assets = 562,027

Assets

Total Assets562,027
Total Current Assets496,718
Long-term Assets65,309
Total Current Assets
Cash And Cash Equivalents 28,038
Short-term Investments 454,881
Other Current Assets 13,799
Total Current Assets  (as reported)496,718
Total Current Assets  (calculated)496,718
+/-0
Long-term Assets
Property Plant Equipment 41,735
Goodwill 3,736
Long-term Assets Other 6,818
Long-term Assets  (as reported)65,309
Long-term Assets  (calculated)52,289
+/- 13,020

Liabilities & Shareholders' Equity

Total Current Liabilities69,367
Long-term Liabilities55,269
Total Stockholder Equity437,284
Total Current Liabilities
Short-term Debt 2,623
Accounts payable 14,926
Other Current Liabilities 51,537
Total Current Liabilities  (as reported)69,367
Total Current Liabilities  (calculated)69,086
+/- 281
Long-term Liabilities
Capital Lease Obligations 43,150
Long-term Liabilities Other 1,780
Long-term Liabilities  (as reported)55,269
Long-term Liabilities  (calculated)44,930
+/- 10,339
Total Stockholder Equity
Common Stock70
Retained Earnings -888,556
Accumulated Other Comprehensive Income 2,194
Other Stockholders Equity 1,323,576
Total Stockholder Equity (as reported)437,284
Total Stockholder Equity (calculated)437,284
+/-0
Other
Capital Stock70
Cash and Short Term Investments 482,919
Common Stock Shares Outstanding 70,766
Current Deferred Revenue281
Liabilities and Stockholders Equity 562,027
Net Debt 17,735
Net Invested Capital 437,284
Net Working Capital 427,351
Property Plant and Equipment Gross 44,883
Short Long Term Debt Total 45,773



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
102,657
87,629
257,217
393,233
365,555
328,353
283,962
435,081
454,507
405,677
567,856
529,193
539,310
489,342
621,444
585,715
562,027
562,027585,715621,444489,342539,310529,193567,856405,677454,507435,081283,962328,353365,555393,233257,21787,629102,657000
   > Total Current Assets 
0
0
0
84,067
66,009
238,481
372,736
345,104
306,354
259,449
377,565
350,770
301,282
467,626
433,890
451,933
410,226
563,929
528,264
496,718
496,718528,264563,929410,226451,933433,890467,626301,282350,770377,565259,449306,354345,104372,736238,48166,00984,067000
       Cash And Cash Equivalents 
0
0
0
82,422
63,650
96,016
92,552
54,951
28,996
49,170
40,807
59,714
30,572
55,143
42,551
43,069
36,280
266,558
110,751
28,038
28,038110,751266,55836,28043,06942,55155,14330,57259,71440,80749,17028,99654,95192,55296,01663,65082,422000
       Short-term Investments 
0
0
0
0
0
137,175
274,884
283,554
269,385
201,730
325,984
280,173
258,797
400,078
379,175
394,302
356,239
286,428
405,886
454,881
454,881405,886286,428356,239394,302379,175400,078258,797280,173325,984201,730269,385283,554274,884137,17500000
       Net Receivables 
0
0
0
140
139
73
122
417
1,663
1,480
108
4,443
4,210
5,165
4,212
7,041
0
1,789
2,955
0
02,9551,78907,0414,2125,1654,2104,4431081,4801,66341712273139140000
       Other Current Assets 
0
0
0
1,505
2,220
5,217
5,178
6,182
6,310
7,069
10,423
6,440
7,703
12,405
12,164
14,562
17,707
932
1,265
13,799
13,7991,26593217,70714,56212,16412,4057,7036,44010,4237,0696,3106,1825,1785,2172,2201,505000
   > Long-term Assets 
0
0
0
18,590
21,620
18,736
20,497
20,451
21,999
24,513
57,516
103,737
104,395
100,230
95,303
87,377
79,116
57,515
57,451
65,309
65,30957,45157,51579,11687,37795,303100,230104,395103,73757,51624,51321,99920,45120,49718,73621,62018,590000
       Property Plant Equipment 
0
0
0
2,836
2,795
2,571
2,396
3,619
3,409
3,446
5,391
52,839
52,124
51,523
50,673
50,078
44,355
43,234
42,577
41,735
41,73542,57743,23444,35550,07850,67351,52352,12452,8395,3913,4463,4093,6192,3962,5712,7952,836000
       Goodwill 
0
0
0
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,736
3,7363,7363,7363,7363,7363,7363,7363,7363,7363,7363,7363,7363,7363,7363,7363,7363,736000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
39,326
37,495
35,744
30,406
28,035
21,213
18,903
0
0
0
00018,90321,21328,03530,40635,74437,49539,3260000000000
       Intangible Assets 
0
0
0
8,800
8,800
8,800
8,800
8,800
8,800
8,800
0
0
0
0
0
0
0
0
0
0
00000000008,8008,8008,8008,8008,8008,8008,800000
       Other Assets 
0
0
0
0
6,289
3,629
5,565
4,296
6,054
8,531
9,063
9,667
12,791
14,565
12,859
12,350
0
10,545
0
0
0010,545012,35012,85914,56512,7919,6679,0638,5316,0544,2965,5653,6296,2890000
> Total Liabilities 
0
0
0
19,060
176,820
19,292
27,400
32,178
35,715
36,353
41,085
90,025
90,011
95,033
100,455
105,286
103,677
98,162
103,818
124,636
124,636103,81898,162103,677105,286100,45595,03390,01190,02541,08536,35335,71532,17827,40019,292176,82019,060000
   > Total Current Liabilities 
0
0
0
14,897
16,939
15,567
23,906
28,601
32,797
33,577
39,415
43,944
43,485
48,636
54,061
56,647
56,358
51,759
58,918
69,367
69,36758,91851,75956,35856,64754,06148,63643,48543,94439,41533,57732,79728,60123,90615,56716,93914,897000
       Short-term Debt 
0
0
0
781
810
810
871
902
1,099
804
862
1,453
1,269
1,733
2,207
2,162
2,247
2,335
2,425
2,623
2,6232,4252,3352,2472,1622,2071,7331,2691,4538628041,099902871810810781000
       Accounts payable 
0
0
0
4,289
7,019
4,217
5,437
8,661
8,337
8,273
8,046
11,590
13,163
12,041
9,820
11,247
12,818
12,305
14,264
14,926
14,92614,26412,30512,81811,2479,82012,04113,16311,5908,0468,2738,3378,6615,4374,2177,0194,289000
       Other Current Liabilities 
0
0
0
9,827
9,110
10,540
17,598
18,628
22,755
23,940
29,740
30,901
29,053
34,862
42,034
45,400
43,540
39,454
44,654
51,537
51,53744,65439,45443,54045,40042,03434,86229,05330,90129,74023,94022,75518,62817,59810,5409,1109,827000
   > Long-term Liabilities 
0
0
0
4,163
159,881
3,725
3,494
3,577
2,918
2,776
1,670
46,081
46,526
46,397
46,394
48,639
47,319
46,403
44,900
55,269
55,26944,90046,40347,31948,63946,39446,39746,52646,0811,6702,7762,9183,5773,4943,725159,8814,163000
       Other Liabilities 
0
0
0
0
2,463
2,463
2,463
2,480
2,918
2,776
1,670
1,622
1,548
1,325
1,225
3,473
0
2,376
0
0
002,37603,4731,2251,3251,5481,6221,6702,7762,9182,4802,4632,4632,4630000
       Deferred Long Term Liability 
0
0
0
0
3,525
0
0
0
0
716
0
0
0
0
0
0
0
0
0
0
000000000071600003,5250000
> Total Stockholder Equity
0
0
0
76,776
-95,903
213,224
341,055
333,377
268,386
223,845
393,432
364,482
315,298
472,490
428,504
433,803
385,487
523,141
481,768
437,284
437,284481,768523,141385,487433,803428,504472,490315,298364,482393,432223,845268,386333,377341,055213,224-95,90376,776000
   Common Stock
0
0
0
25
3,216
36
41
41
41
41
45
45
46
57
57
59
59
70
70
70
7070705959575746454541414141363,21625000
   Retained Earnings Total Equity00-772,111-659,584-596,365-541,394-486,993-418,636-359,559-309,500-305,309-250,735-200,8340000000
   Accumulated Other Comprehensive Income 
0
0
0
-167
-205
4
23
36
50
94
32
-125
-1,109
-1,779
-2,270
-1,353
-556
-338
-359
2,194
2,194-359-338-556-1,353-2,270-1,779-1,109-12532945036234-205-167000
   Capital Surplus 
0
0
0
0
0
0
0
509,339
519,030
529,019
702,855
723,593
734,997
961,205
972,111
1,031,462
1,045,568
1,295,520
0
0
001,295,5201,045,5681,031,462972,111961,205734,997723,593702,855529,019519,030509,3390000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
0
0
0
159,911
205
339,160
501,522
509,339
519,030
529,019
702,855
723,593
734,997
961,205
972,111
1,031,462
1,045,568
1,295,520
1,309,696
1,323,576
1,323,5761,309,6961,295,5201,045,5681,031,462972,111961,205734,997723,593702,855529,019519,030509,339501,522339,160205159,911000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,389
Gross Profit-1,389-1,389
 
Operating Income (+$)
Gross Profit-1,389
Operating Expense-252,552
Operating Income-253,941-253,941
 
Operating Expense (+$)
Research Development189,590
Selling General Administrative64,351
Selling And Marketing Expenses1,389
Operating Expense252,552255,330
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-253,941
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-276,892-230,990
EBIT - interestExpense = -253,941
-292,792
-292,191
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-253,941-276,892
Earnings Before Interest and Taxes (EBITDA)-252,552
 
After tax Income (+$)
Income Before Tax-276,892
Tax Provision--826
Net Income From Continuing Ops-286,350-276,066
Net Income-292,191
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses253,941
Total Other Income/Expenses Net-22,9510
 

Technical Analysis of Zentalis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Zentalis. The general trend of Zentalis is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Zentalis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Zentalis Pharmaceuticals Llc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 13.15 < 13.45 < 16.27.

The bearish price targets are: 10.57 > 10.05 > 9.56.

Tweet this
Zentalis Pharmaceuticals Llc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Zentalis Pharmaceuticals Llc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Zentalis Pharmaceuticals Llc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Zentalis Pharmaceuticals Llc. The current macd is -0.26098177.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Zentalis price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Zentalis. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Zentalis price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Zentalis Pharmaceuticals Llc Daily Moving Average Convergence/Divergence (MACD) ChartZentalis Pharmaceuticals Llc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Zentalis Pharmaceuticals Llc. The current adx is 14.96.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Zentalis shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Zentalis Pharmaceuticals Llc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Zentalis Pharmaceuticals Llc. The current sar is 15.50.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Zentalis Pharmaceuticals Llc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Zentalis Pharmaceuticals Llc. The current rsi is 39.81. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Zentalis Pharmaceuticals Llc Daily Relative Strength Index (RSI) ChartZentalis Pharmaceuticals Llc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Zentalis Pharmaceuticals Llc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Zentalis price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Zentalis Pharmaceuticals Llc Daily Stochastic Oscillator ChartZentalis Pharmaceuticals Llc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Zentalis Pharmaceuticals Llc. The current cci is -120.5806207.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Zentalis Pharmaceuticals Llc Daily Commodity Channel Index (CCI) ChartZentalis Pharmaceuticals Llc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Zentalis Pharmaceuticals Llc. The current cmo is -31.63105753.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Zentalis Pharmaceuticals Llc Daily Chande Momentum Oscillator (CMO) ChartZentalis Pharmaceuticals Llc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Zentalis Pharmaceuticals Llc. The current willr is -97.39726027.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Zentalis Pharmaceuticals Llc Daily Williams %R ChartZentalis Pharmaceuticals Llc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Zentalis Pharmaceuticals Llc.

Zentalis Pharmaceuticals Llc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Zentalis Pharmaceuticals Llc. The current atr is 1.0397507.

Zentalis Pharmaceuticals Llc Daily Average True Range (ATR) ChartZentalis Pharmaceuticals Llc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Zentalis Pharmaceuticals Llc. The current obv is -4,701,066.

Zentalis Pharmaceuticals Llc Daily On-Balance Volume (OBV) ChartZentalis Pharmaceuticals Llc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Zentalis Pharmaceuticals Llc. The current mfi is 36.09.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Zentalis Pharmaceuticals Llc Daily Money Flow Index (MFI) ChartZentalis Pharmaceuticals Llc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Zentalis Pharmaceuticals Llc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Zentalis Pharmaceuticals Llc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Zentalis Pharmaceuticals Llc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.810
Ma 20Greater thanMa 5014.352
Ma 50Greater thanMa 10013.924
Ma 100Greater thanMa 20013.643
OpenGreater thanClose13.030
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Zentalis with someone you think should read this too:
  • Are you bullish or bearish on Zentalis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zentalis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Zentalis Pharmaceuticals Llc

I send you an email if I find something interesting about Zentalis Pharmaceuticals Llc.


Comments

How you think about this?

Leave a comment

Stay informed about Zentalis Pharmaceuticals Llc.

Receive notifications about Zentalis Pharmaceuticals Llc in your mailbox!